Mizuho Securities analyst Irina Rivkind Koffler maintained a Hold rating on Dermira (DERM – Research Report) today and set a price target of $9. The company’s shares opened today at $7.20, close to its 52-week low of $6.00.
Rivkind Koffler observed:
“We believe the company will still require additional capital to conduct Phase III trials of lebrikizumab, and it is unclear whether Almirall could get more aggressive with this asset before that read-out, which is still a few years away. Competitor Leo is hosting an educational session on atopic dermatitis at the 2, so it is also important to monitor the progress of that program, in our view. There are four Phase III trials of tralokinumab in atopic dermatitis posted to www.clinicaltrials.gov which are expected to read out later this year.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.9% and a 42.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.
Dermira has an analyst consensus of Moderate Buy, with a price target consensus of $16.33.
The company has a one-year high of $29.18 and a one-year low of $6.00. Currently, Dermira has an average volume of 653.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.